BACKGROUND: Clostridium difficile infection (CDI) is significantly associated with subsequent all-cause mortality. Although a number of studies have investigated mortality associated with CDI, few have compared all-cause mortality between ribotypes. AIM: We aimed to estimate all-cause mortality following CDI and to investigate the relationship between mortality, ribotype and other available variables. METHODS: We undertook a retrospective cohort study. All patients with toxin-positive CDI in North East England between July 2009 and June 2011 were matched to death registration data. Differences in all-cause 30-day case fatality were explored using Poisson regression with robust error variances. For survival analysis, an accelerated failure time model with generalized gamma distribution was chosen. FINDINGS: In total, 1426 patients were included. All-cause case fatality was 10.2%, 16.4%, 25.7% and 38.1% at 7, 14, 30 and 90 days respectively. In multivariate analysis, ribotype 027 (risk ratio: 1.34; 95% confidence interval: 1.02-1.75) and ribotype 015 (0.46; 0.26-0.82) were significantly associated with higher and lower all-cause 30-day case fatality rates, respectively. In survival analysis, only ribotype 015 had significantly lower predicted mortality (P = 0.008). Patients whose infection was hospital-acquired had significantly higher predicted mortality (P < 0.001). CONCLUSION: This is the first population-based study of comparative mortality between multiple ribotypes. Our study identified a high rate of all-cause mortality following CDI. We found evidence of variability in mortality between ribotypes in this cohort with mortality significantly higher for ribotype 027 at 30 days following diagnosis and significantly lower for ribotype 015.
BACKGROUND:Clostridium difficileinfection (CDI) is significantly associated with subsequent all-cause mortality. Although a number of studies have investigated mortality associated with CDI, few have compared all-cause mortality between ribotypes. AIM: We aimed to estimate all-cause mortality following CDI and to investigate the relationship between mortality, ribotype and other available variables. METHODS: We undertook a retrospective cohort study. All patients with toxin-positive CDI in North East England between July 2009 and June 2011 were matched to death registration data. Differences in all-cause 30-day case fatality were explored using Poisson regression with robust error variances. For survival analysis, an accelerated failure time model with generalized gamma distribution was chosen. FINDINGS: In total, 1426 patients were included. All-cause case fatality was 10.2%, 16.4%, 25.7% and 38.1% at 7, 14, 30 and 90 days respectively. In multivariate analysis, ribotype 027 (risk ratio: 1.34; 95% confidence interval: 1.02-1.75) and ribotype 015 (0.46; 0.26-0.82) were significantly associated with higher and lower all-cause 30-day case fatality rates, respectively. In survival analysis, only ribotype 015 had significantly lower predicted mortality (P = 0.008). Patients whose infection was hospital-acquired had significantly higher predicted mortality (P < 0.001). CONCLUSION: This is the first population-based study of comparative mortality between multiple ribotypes. Our study identified a high rate of all-cause mortality following CDI. We found evidence of variability in mortality between ribotypes in this cohort with mortality significantly higher for ribotype 027 at 30 days following diagnosis and significantly lower for ribotype 015.
Authors: Peter Starzengruber; Luigi Segagni Lusignani; Thomas Wrba; Dieter Mitteregger; Alexander Indra; Wolfgang Graninger; Elisabeth Presterl; Magda Diab-Elschahawi Journal: Wien Klin Wochenschr Date: 2014-06-06 Impact factor: 1.704
Authors: Z Kassam; C Cribb Fabersunne; M B Smith; E J Alm; G G Kaplan; G C Nguyen; A N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2016-02-05 Impact factor: 8.171
Authors: Jonathan Ström; Johan Tham; Fredrik Månsson; Jonas Ahl; Tor C Savidge; Sara M Dann; Fredrik Resman Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Vimalanand S Prabhu; Oliver A Cornely; Yoav Golan; Erik R Dubberke; Sebastian M Heimann; Mary E Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella Journal: Clin Infect Dis Date: 2017-10-01 Impact factor: 9.079
Authors: Anirban Basu; Vimalanand S Prabhu; Mary Beth Dorr; Yoav Golan; Erik R Dubberke; Oliver A Cornely; Sebastian M Heimann; Alison Pedley; Ruifeng Xu; Mary E Hanson; Stephen Marcella Journal: Open Forum Infect Dis Date: 2018-11-15 Impact factor: 3.835
Authors: Dale N Gerding; Ciaran P Kelly; Galia Rahav; Christine Lee; Erik R Dubberke; Princy N Kumar; Bruce Yacyshyn; Dina Kao; Karen Eves; Misoo C Ellison; Mary E Hanson; Dalya Guris; Mary Beth Dorr Journal: Clin Infect Dis Date: 2018-08-16 Impact factor: 9.079